Skip to main content
Premium Trial:

Request an Annual Quote

Compendia Nabs $2.4M SBIR Grant for Oncomine Professional Project; Co-Founder Named CEO

NEW YORK (GenomeWeb News) — Compendia Bioscience yesterday said it has won a $2.4-million SBIR Fast Track Award from the National Cancer Institute to help it further develop its Oncomine Professional technology.
 
Oncomine, designed for biomarker and therapeutic target discovery, validation, and prioritization, combines more than 20,000 cancer transcriptome profiles with an analysis engine and a web application to mine and visualize data, Compendia said.
 
The money for the project, called "Development of Oncomine Professional as a Platform for Biopharmaceutical Research and Development,” also results in Compendia co-founder Dan Rhodes being named CEO of the company. He will also serve as the principal investigator for the project.
 
Current CEO John Freshley will remain with the company as chief business officer overseeing sales, marketing, and corporate development, Compendia said.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.